Who
Allan M. Fox
Director
Company insider
Files Form 4 as: Director and 10% owner, Regenxbio.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $6.1M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 16 Sep 2015
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,815 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —7,768 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,454 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —4,790 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,892 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,486 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,324 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,010 at $0.00 | filing |
| 23 Dec 2021filed 27 Dec 2021 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $1.6M44,908 at $34.92 | filing |
| 23 Dec 2021filed 27 Dec 2021 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $227K6,323 at $35.85 | filing |
| 22 Dec 2021filed 27 Dec 2021 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $2.1M61,638 at $34.40 | filing |
| 17 Sep 2021filed 21 Sep 2021 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $2.2M48,233 at $45.04 | filing |
| 4 Jun 2021filed 8 Jun 2021 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 6 Aug 2020filed 18 Sep 2020 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code G | —90,000 at $0.00 | filing |
| 6 Aug 2020filed 18 Sep 2020 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code G | —90,000 at $0.00 | filing |
| 27 Jul 2020filed 18 Sep 2020 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code G | —225,000 at $0.00 | filing |
News
Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)RGNX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Allan M. Fox; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.